<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02954341</url>
  </required_header>
  <id_info>
    <org_study_id>SJM-CIP-10147</org_study_id>
    <nct_id>NCT02954341</nct_id>
  </id_info>
  <brief_title>CardioMEMS HF System OUS Post Market Study</brief_title>
  <official_title>CardioMEMS HF System OUS Post Market Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this Post Market Study (PMS) is to evaluate the use of the CardioMEMS HF
      System in patients with Class III Heart Failure in a commercial setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from device/system related complications</measure>
    <time_frame>Two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from pressure sensor failure.</measure>
    <time_frame>Two year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Annualized HF hospitalization rate at 1 year compared to the HF hospitalization rate in the year prior to enrollment.</measure>
    <time_frame>One year</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Heart Failure</condition>
  <condition>Left-Sided Heart Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CardioMEMS HF System</intervention_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with New York Heart Association (NYHA) Class III Heart Failure (HF) who have
        experienced a heart failure hospitalization within the past 12 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Written informed consent obtained from subject

          2. ≥ 18 years of age

          3. Diagnosis of NYHA Class III Heart Failure

          4. At least 1 HF hospitalization within 12 months of Baseline visit

          5. Subjects with reduced LVEF heart failure should be receiving a beta blocker for 3
             months and an ACE-I or ARB for one month unless in the investigator's opinion, the
             subject is intolerant to beta blockers, ACE-I or ARB.

          6. Subjects with a BMI ≤ 35. Subjects with BMI &gt;35 will require their chest circumference
             to be measured at the axillary level, if &gt; 65 inches the patient will not be eligible
             for the study.

          7. Subjects with pulmonary artery branch diameter ≥ 7mm - (implant target artery -
             assessed during the RHC)

          8. Subjects willing and able to comply with the follow-up requirements of the study

        Exclusion Criteria:

          1. Subjects with an active infection

          2. Subjects with history of recurrent (&gt; 1) pulmonary embolism or deep vein thrombosis

          3. Subjects who, in the Investigator's opinion, are unable to tolerate a right heart
             catheterization

          4. Subjects who have had a major cardiovascular event (e.g., myocardial infarction, open
             heart surgery, stroke, etc.) within 2 months of Baseline Visit

          5. Subjects with Cardiac Resynchronization Device (CRT) implanted &lt; 3 months prior to
             enrollment

          6. Subjects with a Glomerular Filtration Rate (GFR) &lt; 25 ml/min (obtained within 2 weeks
             of the baseline visit) who are non-responsive to diuretic therapy or who are on
             chronic renal dialysis

          7. Subjects with congenital heart disease or mechanical right heart valve(s)

          8. Subjects likely to undergo heart transplantation or VAD within 6 months of baseline
             visit

          9. Subjects with known coagulation disorders

         10. Subjects with a hypersensitivity or allergy to aspirin, and/or clopidogrel (not
             applicable for subjects taking anti-coagulation therapy or other approved
             anti-platelets therapy).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin R Cowie, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Brompton &amp; Harefield NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie Le Bail</last_name>
    <email>sophie.lebail@abbott.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Poornima Sood</last_name>
    <email>Poornima.sood@abbott.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <state>Queensland</state>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Troisfontaines, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kasper Rossing, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal De Groote, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Bromptom Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 21, 2016</study_first_submitted>
  <study_first_submitted_qc>November 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 3, 2016</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

